BACKGROUND: Niemann-Pick disease type C is a rare lysosomal storage disorder. We evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann-Pick disease type C. METHODS: In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years of age or older with genetically confirmed Niemann-Pick disease type C in a 1:1 ratio to receive NALL for 12 weeks, followed by placebo for 12 weeks, or to receive placebo for 12 weeks, followed by NALL for 12 weeks. NALL or matching placebo was administered orally two to three times per day, with patients 4 to 12 years of age receiving weight-based doses (2 to 4 g per day) and those 13 years of age or older receiving a dose of 4 g per day. The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status). Secondary end points included scores on the Clinical Global Impression of Improvement, the Spinocerebellar Ataxia Functional Index, and the Modified Disability Rating Scale. Crossover data from the two 12-week periods in each group were included in the comparisons of NALL with placebo. RESULTS: A total of 60 patients 5 to 67 years of age were enrolled. The mean baseline SARA total scores used in the primary analysis were 15.88 before receipt of the first dose of NALL (60 patients) and 15.68 before receipt of the first dose of placebo (59 patients; 1 patient never received placebo). The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001). The results for the secondary end points were generally supportive of the findings in the primary analysis, but these were not adjusted for multiple comparisons. The incidence of adverse events was similar with NALL and placebo, and no treatment-related serious adverse events occurred. CONCLUSIONS: Among patients with Niemann-Pick disease type C, treatment with NALL for 12 weeks led to better neurologic status than placebo. A longer period is needed to determine the long-term effects of this agent in patients with Niemann-Pick disease type C. (Funded by IntraBio; ClinicalTrials.gov number, NCT05163288; EudraCT number, 2021-005356-10.).
- MeSH
- dítě MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- klinické křížové studie MeSH
- látky ovlivňující centrální nervový systém * aplikace a dávkování terapeutické užití MeSH
- leucin analogy a deriváty terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- Niemannova-Pickova nemoc typu C * komplikace diagnóza farmakoterapie genetika MeSH
- předškolní dítě MeSH
- sběr dat MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- předškolní dítě MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
108 stran : ilustrace, tabulky
Using real examples from oncology trials, but keeping it simple, this concise resource explains the basic principles of medical statistics so that you can better appraise clinical trial results. Key concepts covered in this book include: • hypothesis testing • Kaplan–Meier curves and other graphic representations of data • calculating the power of a study • the stopping rules for efficacy and futility.' Fast Facts: Medical Statistics' is aimed at all clinicians, clinical scientists, medical writers and regulatory personnel who need a better understanding of the statistical terms and methods used in the planning of studies and the analysis of clinical trial data. If you have ever wanted to know what a type I error is, how an odds ratio is calculated or what a forest plot is really all about, then this is the book for you.Contents:• Statistical inference• Analysis of time-to-event endpoints• Power and sample size• Multiplicity• Interim analysis• Modeling• Graphical methods
- MeSH
- klinické zkoušky jako téma MeSH
- lékařská onkologie MeSH
- statistika jako téma MeSH
- Publikační typ
- příručky MeSH
- NLK Obory
- statistika, zdravotnická statistika
- onkologie
